同和药业：阿戈美拉汀、奥吡卡朋药品注册证书获得韩国食品药品安全部颁发

Core Viewpoint - The company Tonghua Dongbao Pharmaceutical has received registration certificates from the Korean Ministry of Food and Drug Safety (MFDS) for two drugs, Agomelatine and Opicapone, which will enhance its international market presence [1] Group 1: Drug Approvals - Agomelatine is indicated for the treatment of adult depression [1] - Opicapone is a COMT inhibitor primarily used for the treatment of Parkinson's disease and Parkinson's syndrome [1] Group 2: Market Impact - The approval of Agomelatine and Opicapone for the Korean market will positively contribute to the company's efforts to expand its international business [1]